COR — Cencora Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeLarge CapNeutral
- $40.40bn
- $42.74bn
- $262.17bn
- 76
- 50
- 96
- 86
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 15.39 | ||
| PEG Ratio (f) | 0.6 | ||
| EPS Growth (f) | 34.73% | ||
| Dividend Yield (f) | 1.01% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 77.4 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 11.7 | ||
| Price to Sales | 0.15 | ||
| EV to EBITDA | 12.71 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 17.35% | ||
| Return on Equity | 1124.39% | ||
| Operating Margin | 0.91% | ||
Financial Summary
| Year End 30th Sep | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 179,589.12 | 189,893.93 | 213,988.84 | 238,587.01 | 262,173.41 | 283,936.58 | 300,563.81 | 9.32% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +16.14 | -10.5 | +37.49 | +11.39 | -3.12 | +41.38 | +8.78 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cencora, Inc. is a global pharmaceutical solutions company centered on improving the lives of people and animals around the world. The Company is engaged in the delivery of pharmaceuticals, healthcare products, and solutions. It connects manufacturers, providers, pharmacies, and patients to help them navigate the healthcare system from start to finish. In addition to its core distribution services, it offers a portfolio of solutions to improve the health system's business performance, safety, and patient experience. It delivers solutions for veterinarians, livestock producers, ag-retailers, and manufacturers that make a difference in their businesses and the health of animals. Its solutions and services are designed to help every aspect of the animal health business, from supporting animal care and client experience to managing day-to-day operations. It helps pharmacies and other care providers access the full-line and specialty products they need to care for their patients.
Directors
- Steven Collis CHM (60)
- James Cleary CFO (58)
- Silvana Battaglia CHO (54)
- Gina Clark EVP (64)
- Elizabeth Campbell EVP (47)
- John Chou EVP (65)
- Leslie Donato EVP (52)
- Robert Mauch EVP (54)
- Jane Henney LED (74)
- Ornella Barra DRC (69)
- D. Mark Durcan IND (60)
- Richard Gochnauer IND (72)
- Lon Greenberg IND (71)
- Kathleen Hyle IND (63)
- Michael Long IND (63)
- Henry McGee IND (68)
- Dennis Nally IND (69)
- Last Annual
- September 30th, 2023
- Last Interim
- September 30th, 2023
- Incorporated
- March 16th, 2001
- Public Since
- May 28th, 1996
- No. of Shareholders
- 2,170
- No. of Employees
- 42,000
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 200,712,338
- Address
- 1 West First Avenue, CONSHOHOCKEN, 19428
- Web
- https://www.cencora.com/
- Phone
- +1 6107277000
- Contact
- Bennett Murphy
- Auditors
- Ernst & Young LLP
Upcoming Events for COR
Q1 2024 Cencora Inc Earnings Release
Cencora Inc Annual Shareholders Meeting
Q2 2024 Cencora Inc Earnings Release
Similar to COR
Abbott Laboratories
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Agiliti
New York Stock Exchange
Alcon AG
New York Stock Exchange
Artivion
New York Stock Exchange
FAQ
What is the Cencora share price?
As of Today at 18:05 UTC, shares in Cencora are trading at $201.30. This share price information is delayed by 15 minutes.
How has the Cencora share price performed this year?
Shares in Cencora last closed at $201.30 and the price had moved by +21.61% over the past 365 days. In terms of relative price strength the Cencora share price has outperformed the S&P500 Index by +7.39% over the past year.
What are the analyst and broker recommendations for Cencora?
The overall consensus recommendation for Cencora is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Cencora dividend yield?
The Cencora dividend yield is 0.96% based on the trailing twelve month period.
Does Cencora pay a dividend?
Last year, Cencora paid a total dividend of $1.94, and it currently has a trailing dividend yield of 0.96%.Looking ahead, the next dividend pay date is 2023-11-27.
When does Cencora next pay dividends?
We do not have data on when Cencora is to next pay dividends. The historic dividend yield on Cencora shares is currently 0.96%.
How do I buy Cencora shares?
To buy shares in Cencora you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cencora?
As of the previous close price of $201.30, shares in Cencora had a market capitalisation of $40.40bn.
Where are Cencora shares listed?
Here are the trading details for Cencora:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: COR
What kind of share is Cencora?
Based on an overall assessment of its quality, value and momentum Cencora is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cencora share price forecast for 2023?
The analyst consensus target price for shares in Cencora is $212.83. That is 5.73% above the last closing price of $201.30.
Analysts covering Cencora currently have a consensus Earnings Per Share (EPS) forecast of $12.90 for the next financial year.
What is the trend in the Cencora share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cencora. Over the past six months, its share price has outperformed the S&P500 Index by +10.25%.
As of the last closing price of $201.30, shares in Cencora were trading +13.7% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cencora PE Ratio?
The Cencora PE ratio based on its reported earnings over the past 12 months is 15.39. The shares last closed at $201.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cencora?
Cencora's management team is headed by:
- Steven Collis - CHM
- James Cleary - CFO
- Silvana Battaglia - CHO
- Gina Clark - EVP
- Elizabeth Campbell - EVP
- John Chou - EVP
- Leslie Donato - EVP
- Robert Mauch - EVP
- Jane Henney - LED
- Ornella Barra - DRC
- D. Mark Durcan - IND
- Richard Gochnauer - IND
- Lon Greenberg - IND
- Kathleen Hyle - IND
- Michael Long - IND
- Henry McGee - IND
- Dennis Nally - IND